159 related articles for article (PubMed ID: 22910183)
21. Process for immune defect and chromosomal translocation during early thymocyte development lacking ATM.
Isoda T; Takagi M; Piao J; Nakagama S; Sato M; Masuda K; Ikawa T; Azuma M; Morio T; Kawamoto H; Mizutani S
Blood; 2012 Jul; 120(4):789-99. PubMed ID: 22709691
[TBL] [Abstract][Full Text] [Related]
22. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
23. Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
Fuster O; Llop M; Dolz S; García P; Such E; Ibáñez M; Luna I; Gómez I; López M; Cervera J; Montesinos P; Moscardó F; Cordón L; Solves P; de Juan I; Palanca S; Bolufer P; Sanz MÁ; Barragán E
Leuk Res; 2013 Dec; 37(12):1690-6. PubMed ID: 24199710
[TBL] [Abstract][Full Text] [Related]
24. MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer.
Liang HB; Cao Y; Ma Q; Shu YJ; Wang Z; Zhang F; Ye YY; Li HF; Xiang SS; Song XL; Xu Y; Zhang YC; Bao RF; Yuan RY; Zhang YJ; Hu YP; Jiang L; Li ML; Wang XA; Wu XS; Wu WG; Zhao S; Fand Y; Cui XP; Lu YS; Zhou J; Zheng L; Gong W; Liu YB
Cell Physiol Biochem; 2017; 41(5):2117-2131. PubMed ID: 28427077
[TBL] [Abstract][Full Text] [Related]
25. Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice.
Zhang J; Xiao Y; Guo Y; Breslin P; Zhang S; Wei W; Zhang Z; Zhang J
Leukemia; 2011 Dec; 25(12):1857-68. PubMed ID: 21926961
[TBL] [Abstract][Full Text] [Related]
26. Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells.
Tavner F; Frampton J; Watson RJ
Oncogene; 2007 Apr; 26(19):2727-35. PubMed ID: 17072340
[TBL] [Abstract][Full Text] [Related]
27. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
Yan D; Jobe F; Hutchison RE; Mohi G
Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
[TBL] [Abstract][Full Text] [Related]
28. The use of MYBL2 as a novel candidate biomarker of cervical cancer.
Martin CM; Astbury K; Kehoe L; O'Crowley JB; O'Toole S; O'Leary JJ
Methods Mol Biol; 2015; 1249():241-51. PubMed ID: 25348311
[TBL] [Abstract][Full Text] [Related]
29. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family.
Li ZB; Chu HT; Jia M; Li L
Biochem Biophys Res Commun; 2020 May; 525(3):581-588. PubMed ID: 32115147
[TBL] [Abstract][Full Text] [Related]
31. MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential.
Bayley R; Ward C; Garcia P
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188407. PubMed ID: 32853735
[TBL] [Abstract][Full Text] [Related]
32. The role of MYB proto-oncogene like 2 in tamoxifen resistance in breast cancer.
Li X; Zhang X; Wu CC; Li PP; Fu YM; Xie LH; Sun SS; Zhou YY; Zhu BL
J Mol Histol; 2021 Feb; 52(1):21-30. PubMed ID: 33141360
[TBL] [Abstract][Full Text] [Related]
33. HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells.
Zhang H; Li H; Xi HS; Li S
Blood; 2012 Mar; 119(11):2595-607. PubMed ID: 22275380
[TBL] [Abstract][Full Text] [Related]
34. Mybl2 (Bmyb) maps to mouse chromosome 2 and human chromosome 20q 13.1.
Noben-Trauth K; Copeland NG; Gilbert DJ; Jenkins NA; Sonoda G; Testa JR; Klempnauer KH
Genomics; 1996 Aug; 35(3):610-2. PubMed ID: 8812502
[TBL] [Abstract][Full Text] [Related]
35. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
36. Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143.
Li M; Liu Y; Liu J; Li W; Li N; Xue D; Zhang X; Wang P
Aging (Albany NY); 2019 Nov; 11(22):10626-10643. PubMed ID: 31756170
[TBL] [Abstract][Full Text] [Related]
37. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
38. Morgana acts as an oncosuppressor in chronic myeloid leukemia.
Di Savino A; Panuzzo C; Rocca S; Familiari U; Piazza R; Crivellaro S; Carrà G; Ferretti R; Fusella F; Giugliano E; Camporeale A; Franco I; Miniscalco B; Cutrin JC; Turco E; Silengo L; Hirsch E; Rege-Cambrin G; Gambacorti-Passerini C; Pandolfi PP; Papotti M; Saglio G; Tarone G; Morotti A; Brancaccio M
Blood; 2015 Apr; 125(14):2245-53. PubMed ID: 25678499
[TBL] [Abstract][Full Text] [Related]
39. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.
Kung AL; Rebel VI; Bronson RT; Ch'ng LE; Sieff CA; Livingston DM; Yao TP
Genes Dev; 2000 Feb; 14(3):272-7. PubMed ID: 10673499
[TBL] [Abstract][Full Text] [Related]
40. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
